SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Piccart MJ, De Valeriola D, Paridaens R, et al. Six year results of a multimodality treatment strategy for locally advanced breast cancer. Cancer. 1988; 62: 25012506.
  • 2
    Hortobagyi GN, Ames FC, Buzdar AU, et al. Management of Stage III breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. 1988; 62: 25072516.
  • 3
    Swain SM, Sorace RA, Bagley CS, et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res. 1987; 47: 38893894.
  • 4
    Valagussa P, Zambetti M, Bonadonna G, Zucali R, Mezzanotte G, Veronesi U. Prognostic factors in locally advanced noninflammatory breast cancer: long-term results following primary chemotherapy. Breast Cancer Res Treat. 1990; 15: 137147.
  • 5
    Jacquillat CL, Weil M, Baillet F, et al. Results of neoadjuvant chemotherapy and radiation therapy in breast conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer. 1990; 16: 119129.
  • 6
    Schwartz GF, Birchansky CA, Komarnicky LT, et al. Induction chemotherapy followed by breast conservation for locally advanced breast cancer. Cancer. 1994; 73: 362369.
  • 7
    Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999; 17: 460467.
  • 8
    Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 1990; 82: 15391545.
  • 9
    Hayward JL, Rubens RD, Carbone PP, Heuson JC, Kumaoka S, Segaloff A. Assessment of responses to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland. Br J Cancer. 1978; 14: 12911292.
  • 10
    Masters JRW, Camplejohn RS, Millis RR, Rubens RD. Histologic grade, elastosis, DNA ploidy and response to chemotherapy. Br J Cancer. 1987; 55: 455457.
  • 11
    Owainati AA, Robins RA, Hinton C, et al. Tumor aneuploidy, prognostic parameters and survival in primary breast cancer. Br J Cancer. 1987; 55: 449454.
  • 12
    Aas T, Geisler S, Paulsen T, et al. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer: clinical experience and parameters predicting outcome. Acta Oncol. 1996; 35( Suppl 5): 58.
  • 13
    Sjostrom J, Krajewski S, Franssila K, et al. A multivariate analysis of tumor biologic factors predicting response to cytotoxic treatment in advanced breast cancer. Br J Cancer. 1998; 78(6): 812815.
  • 14
    Resnick JM, Sneige N, Kemp BL, et al. p53 and c-erbB-2 expression and response to preoperative chemotherapy in locally advanced breast carcinoma. Breast Dis. 1995; 8: 149158.
  • 15
    Thor AD, Berry DA, Budman DR, et al. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998; 90: 13461360.
  • 16
    Paik S, Bryant J, Park C, et al. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998; 90: 13611370.
  • 17
    Vincent-Salomon A, Carton M, Freneaux P, et al. ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathologic response to preoperative high-dose anthracycline-based chemotherapy. Eur J Cancer. 2000; 36: 586591.
  • 18
    Yang QF, Sakurai T, Yoshimura G, et al. Expression of Bcl-2 but not Bax or p53 with in vitro resistance to a series of anticancer drugs in breast cancer. Breast Cancer Res Treat. 2000; 61: 211216.
  • 19
    Mottolese M, Benevolo M, Del Monte G, et al. Role of p53 and Bcl-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy. J Cancer Res Clin Oncol. 2000; 126: 722729.
  • 20
    Jalava P, Collan Y, Kuopio T, Juntti-Patinen L, and Kronqvist P. Bcl-2 immunostaining: a way to finding unresponsive postmenopausal N+ breast cancer patients. Anticancer Res. 2000; 20: 12131220.
  • 21
    American Joint Committee on Cancer. Manual for staging of cancer, 6th ed. Philadelphia: Lippincott, 1998.
  • 22
    Black MM, Speer FD. Nuclear structure in cancer tissue. Surg Gynecol Obstet. 1957; 105: 97102.
  • 23
    Hopman AH, Ramaekers FC, Raap AK, et al. In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors. Histochemistry. 1988; 89: 307316.
  • 24
    Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997; 15(7): 24832493.
  • 25
    Silvertrini R, Daidone MG, Valagussa P, Salvadori B, Rovini D, Bonadonna D. Cell kinetics as a prognostic marker in locally advanced breast cancer. Cancer Treat Rep. 1987; 71: 375379.
  • 26
    Abu-Farsakh H, Sneige N, Atkinson N, Hortobagyi G. Pathologic predictors of tumor response to preoperative chemotherapy in patients with locally advanced cancer. Breast J. 1995; 1: 96101.
  • 27
    Page DL, Gray R, Allred DC, et al. Prediction of node-negative breast cancer outcome by histologic grading and S-phase analysis by flow cytometry, an Eastern Cooperative Group study (2192). Am J Clin Oncol. 2001; 24: 1018.
  • 28
    Hietanen P, Blomqvist C, Wasenus V-M, Niskanen E, Franssila K, Nordling S. Do DNA ploidy and S-phase fraction in primary tumor predict the response to chemotherapy in metastatic breast cancer? Br J Cancer. 1995; 71: 10291032.
  • 29
    Colleoni M, Orvieto E, Nole F, et al. Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer. 1999; 35: 574579.
  • 30
    Remvikos Y, Jouve M, Beuzeboc P, et al. Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspirates. Eur J Cancer. 1993; 29A: 18431848.
  • 31
    Makris A, Powles TJ, Dowsett M, et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res. 1997; 3: 593600.
  • 32
    Zhu X, Mancini MA, Chang CH, et al. Characterization of a novel 350-kilodalton nuclear phosphoprotein that is specifically involved in mitotic-phase progression. Mol Cell Biol. 1995; 15: 50175029.
  • 33
    Clark GM, Allred DC, Hilsenbeck SG, et al. Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. Cancer Res. 1997; 57: 55055508.
  • 34
    Chang J, Powles TJ, Allred DC, et al. Biologic makers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol. 1999; 17: 30583063.
  • 35
    Feig LA, Schaffhausen B. Signal transduction. The hunt for Ras targets. Nature. 1994; 370: 508509.
  • 36
    Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with the amplification of Her2-neu oncogene. Science. 1987; 235: 177182.
  • 37
    Gusterson BA, Machin LG, Gullick WJ, et al. c-erbB-2 in benign and malignant breast disease. Br J Cancer. 1988; 58: 453457.
  • 38
    Allred DC, Clark GM, Tandon AK, et al. Her-2/neu in node negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol. 1992; 10: 599605.
  • 39
    Gusterson BA, Gelber RD, Goldhiesch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol. 1992; 10: 10491059.
  • 40
    Berger MS, Locher GW, Saurer S. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res. 1988; 48(5): 12381243.
  • 41
    Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 1989; 7(8): 11201128.
  • 42
    Guerin M, Gabillot M, Mathieu MC, Travagli JP. Structure and expression of c-erbB-2 and EFG receptor gene in inflammatory and noninflammatory breast cancer: prognostic significance. Int J Cancer. 1989; 43: 201208.
  • 43
    Zeillinger R, Kury F, Czerwenka K, et al. HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene. 1989; 4(1): 109114.
  • 44
    Wright C, Angus B, Nicholson S, et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989; 15: 49(8): 2087–2090.
  • 45
    Borg A, Linell F, Idvall I, et al. HER2/neu amplification and comedo type breast carcinoma. Lancet. 1989; 3: 12681269.
  • 46
    Muss HB, Thor AD, Berry DA, et al. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994; 330(18): 12601206.
  • 47
    Clahsen PC, van de Velde CJ, Duval C, et al. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol. 1998; 16: 470479.
  • 48
    Rozen S, Vincent-Salomon A, Zafrani B, et al. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer. 1998; 79: 2733.
  • 49
    Geisler S, Lonning PE, Aas T, et al. Influence of TP53 gene alteration and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 2001; 61: 25052512.